Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Eagle to acquire Arsia Therapeutics

by Ann M. Thayer
November 21, 2016 | A version of this story appeared in Volume 94, Issue 46

Seeking to enter the biologics space, Eagle Pharmaceuticals will pay $30 million to acquire Arsia Therapeutics. Eagle may also pay up to $48 million more in milestone payments. Founded in 2013 by MIT professors Robert Langer and Alexander Klibanov, Arsia has technology for formulating and delivering proteins subcutaneously at high concentrations. Eagle plans to use it to develop biosimilars. It will also set up a Biologics Innovation Center in Arsia’s headquarters city of Cambridge, Mass.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.